Cargando…

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib

Triple negative breast cancer (TNBC) is characterized by lack of expression of the estrogen and progesterone receptors and HER2, which are common therapeutic targets. CDK4/6 inhibitor Palbociclib has been approved as an anti-cancer agent for breast cancer. However, identifying biomarkers that predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yuanhang, Liao, Han, Xie, Rong, Zhang, Yue, Zheng, Renjing, Chen, Jianying, Zhang, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729088/ https://www.ncbi.nlm.nih.gov/pubmed/33330073 http://dx.doi.org/10.3389/fonc.2020.590813

Ejemplares similares

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer
por: Zhang, Yue, et al.
Publicado: (2023)

MiRNA 3613-5p and MiRNA 3916 rescued the inhibition of cell migration in CNOT2 depleted MDA-MD-231 cells
por: Sohn, Eun Jung
Publicado: (2020)

MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review
por: Volovat, Simona Ruxandra, et al.
Publicado: (2020)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer
por: Wang, Xianzhe, et al.
Publicado: (2023)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

MiR-3613-3p affects cell proliferation and cell cycle in hepatocellular carcinoma
por: Zhang, Donghui, et al.
Publicado: (2017)

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
por: Peng, Jingyu, et al.
Publicado: (2021)

Influence of Clinical Factors on miR-3613-3p Expression in Colorectal Cancer
por: Gil-Kulik, Paulina, et al.
Publicado: (2023)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer
por: Pedroza, Diego A., et al.
Publicado: (2021)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
por: Ninio-Many, Lihi, et al.
Publicado: (2020)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Design, synthesis, and anticancer activity of three novel palbociclib derivatives
por: Li, Tian, et al.
Publicado: (2022)

High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer
por: Yi, Minhan, et al.
Publicado: (2021)

Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
por: Nelson, Kellie Lynn, et al.
Publicado: (2017)

The Tumor Cytosol miRNAs, Fluid miRNAs, and Exosome miRNAs in Lung Cancer
por: Qin, Xin, et al.
Publicado: (2015)

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer
por: Li, Huihui, et al.
Publicado: (2023)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Palbociclib-Induced Pneumonitis: A Case Report and Review of the Literature
por: Sarkisian, Saro, et al.
Publicado: (2020)

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
por: Ji, Wenfei, et al.
Publicado: (2020)

HSulf-1 and palbociclib exert synergistic antitumor effects on RB-positive triple-negative breast cancer
por: Chen, Fengxia, et al.
Publicado: (2020)

Exosome-Mediated Transfer of miR-3613-5p Enhances Doxorubicin Resistance by Suppression of PTEN Expression in Breast Cancer Cells
por: Luo, Lin, et al.
Publicado: (2022)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

A Key mRNA-miRNA-lncRNA Competing Endogenous RNA Triple Sub-network Linked to Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Zhang, Junjie, et al.
Publicado: (2020)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

MiRNAs Predict the Prognosis of Patients with Triple Negative Breast Cancer: A Meta-Analysis
por: Liu, Yanli, et al.
Publicado: (2017)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
por: Huang, Yajing, et al.
Publicado: (2020)

Bioinformatics and Expression Analyses of miR-639, miR-641, miR-1915-3p and miR-3613-3p in Colorectal Cancer Pathogenesis
por: Avsar, Rusen, et al.
Publicado: (2023)

Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
por: Poumeaud, François, et al.
Publicado: (2022)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aalsln5i80t6osqdfera2u74hu